3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q1 FY25.
3B

3B Blackbio DX Ltd

Q1 FY25Healthcare Services

3B Blackbio DX Q1 FY25 earnings call: Revenue & Margins

Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹19Cr
+35.7% YoY
−17.4% QoQ
Net profit
₹11Cr
+57.1% YoY
+22.2% QoQ
Margin
56%
+11 pp YoY
+13 pp QoQ

Based on 3B Blackbio DX Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24. EBITDA Q1 FY 2024-25: Rs. 1,458.53 lakh.

From 3B Blackbio DX Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24.
  • Diagnostics business standalone (non-COVID) sales rose to ₹1,496.92 lakh in Q1 FY 2024-25 from ₹1,054.13 lakh in Q1 FY 2023-24 (~42% increase).
  • Molecular diagnostic (MDx) kits export sales increased to ₹346.93 lakh in Q1 FY 2024-25 from ₹163.51 lakh in Q1 FY 2023-24 (+112%).
  • UK subsidiary TRUPCR® Europe Ltd. revenue grew 85% year-on-year in Q1 FY 2024-25 (from GBP 163,887 to GBP 309,204).
  • Non-COVID sales effective growth for Q1 FY 2024-25 is approx. 40%, aligned with expected 20-25% growth outlook.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).
  • Funds will also be deployed in a joint venture created in Manchester, UK, depending on need (Page 34).
  • The Manchester site houses sales, marketing, technical support, and R&D, with projected growth of 40%-50% for the fiscal year (Page 23).
  • Expansion is ongoing and tied to strategic inorganic growth via acquisitions if financially viable, else share buybacks may be considered (Page 34).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides related insights as follows: - The company has signed over 15 long-term contracts (2-3 years) under a Reagent-Rental Model, contributing to projected business of 20%-25% in the current and coming years (Page 33).

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q1 FY25 results — key figures

3B Blackbio DX Ltd Q1 FY25 reported results vs Q1 FY24, ₹ crore
₹ CrQ1 FY25Q1 FY24YoYQ4 FY24QoQ
Revenue1914+35.7%23-17.4%
Operating profit (EBITDA)116+83.3%10+10%
Operating margin56%45%+11 pp43%+13 pp
Profit before tax149+55.6%140%
Net profit (PAT)117+57.1%9+22.2%
EPS (₹)12.979.71+33.6%10.33+25.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q1 FY25 results?

Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24. EBITDA Q1 FY 2024-25: Rs. 1,458.53 lakh.

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.